SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction
- 8 March 2004
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (5), 1291-1294
- https://doi.org/10.1016/j.bmcl.2003.12.027
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Phosphodiesterase 5 inhibitors: current status and potential applicationsNature Reviews Drug Discovery, 2002
- The discovery of novel, potent and selective PDE5 inhibitorsBioorganic & Medicinal Chemistry Letters, 2001
- Optimization of Substituted N-3-Benzylimidazoquinazolinone Sulfonamides as Potent and Selective PDE5 InhibitorsJournal of Medicinal Chemistry, 2000
- N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile DysfunctionJournal of Medicinal Chemistry, 2000
- Cyclic GMP Phosphodiesterase-5: Target of SildenafilPublished by Elsevier BV ,1999
- Synthesis and evaluation of potent and selective c-GMP phosphodiesterase inhibitorsBioorganic & Medicinal Chemistry Letters, 1999
- New aryl/heteroaryl CN bond cross-coupling reactions via arylboronic acid/cupric acetate arylationTetrahedron Letters, 1998
- Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive ActivityJournal of Medicinal Chemistry, 1997
- α-Trifluoromethylmethylene and α-trifluoromethylethylidene γ-butyrolactonesTetrahedron Letters, 1993
- Utilization of operational schemes for analog synthesis in drug designJournal of Medicinal Chemistry, 1972